The board of directors of SSY Group Limited informed the shareholders of the company and potential investors that, based on a preliminary review of the company's unaudited consolidated management accounts for the year ended 31 December 2017, the profit attributable to equity holders of the company for the year ended 31 December 2017 is expected to increase significantly and record an increase ranging from 30% to 40% as compared with that of the year ended 31 December 2016. Such expected increase was mainly due to, among other things, (i) increases in sales volume and average selling price of intravenous infusion solutions and (ii) increase in overall gross profit margin of the Group's products due to a better product mix from products with higher profit margins and the Group's continuous cost control measures.